Subtle Medical Expands in Latin America: SubtleHD™ Now Commercially Available in Chile, Distributed by Hospiline
SubtleHD™ is an FDA-cleared and CE-marked deep learning technology that transforms the quality of MRI images and enables up to 80% time savings on some sequences. It integrates seamlessly into existing clinical workflows, extending the life and performance of existing MRI scanners, an especially critical need across Latin America, where aging imaging infrastructure is common.
In Brazil, for example, over 66% of MRI scanners are more than six years old, while demand for MRI exams is growing rapidly, estimated at 30,000 scans per million inhabitants per year. As patient volumes rise, public institutions often face long wait times, and many providers are challenged to meet demand with outdated equipment.
SubtleHD helps imaging providers unlock new scan slots without purchasing new hardware, improving operational efficiency and patient throughput. With SubtleHD, healthcare institutions in Chile can now benefit from:
Improved image quality even on older MRI systems
Faster exam times, helping reduce patient backlog
Vendor-neutral compatibility with existing infrastructure
"We're thrilled to expand access to SubtleHD in Chile," said Josh Gurewitz, Chief Commercial Officer, at Subtle Medical. "With the support of Hospiline, imaging providers across the region can now harness AI to overcome infrastructure gaps, boost productivity, and elevate diagnostic confidence."
About Subtle Medical
Subtle Medical is a leading provider of AI-powered imaging solutions, optimizing scan efficiency and image quality across radiology. Recognized as a CB Insights GenAI 50 company and a two-time CB Insights Top AI 100 and Digital Health 150 company, Subtle Medical is committed to driving innovation in medical imaging. Deployed globally across 900+ scanners worldwide, Subtle Medical's solutions help imaging centers and hospitals improve workflow efficiency, increase scanner sustainability, and elevate patient care. Learn more and request a demo at www.subtlemedical.com.
About Hospiline
Hospiline is a trusted distributor of advanced medical technologies across Latin America, committed to delivering innovative solutions that elevate patient care and clinical performance. United by a vision of excellence, we partner with leading global healthcare innovators to bring the most modern, effective technologies to hospitals, clinics, and imaging centers throughout the region. Our mission is to support and optimize the healthcare ecosystem by ensuring access to cutting-edge medical products that enhance outcomes and drive operational efficiency.
Media ContactAnna Menyhart-BorroniHead of Marketinganna@subtlemedical.com
Source:TheGlobalEconomy.comSciELO BrazilUMass Medical School eScholarship
SOURCE Subtle Medical, Inc.
Fehler beim Abrufen der Daten
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Walmart recalls frozen shrimp over potential radioactive contamination
Walmart has recalled frozen, raw shrimp sold in 13 states because federal health officials say it could have potential radioactive contamination. The U.S. Food and Drug Administration asked Walmart to pull three lots of Great Value brand frozen shrimp from stores after federal officials detected Cesium-137, a radioactive isotope, in shipping containers and a sample of breaded shrimp imported from Indonesia. The products could pose a 'potential health concern' for people exposed to low levels of Cesium-137 over time, FDA officials said. 'If you have recently purchased raw frozen shrimp from Walmart that matches this description, throw it away,' FDA officials said in a statement. The risk from the recalled shrimp is 'quite low,' said Donald Schaffner, a food safety expert at Rutgers University. Cesium-137 is a byproduct of nuclear reactions, including nuclear bombs, testing, reactor operations and accidents. It's widespread around the world, with trace amounts found in the environment, including soil, food and air. The level detected in the frozen breaded shrimp was far lower than FDA intervention levels. However, the agency said that avoiding potentially contaminated products could reduce exposure to low-level radiation that could lead to health problems over time. The FDA is investigating reports of Cesium-137 contamination in shipping containers and products processed by P.T. Bahari Makmur Sejati, doing business as BMS Foods of Indonesia. U.S. Customs and Border Protection officials alerted FDA that they found Cesium-137 in shipping containers sent to U.S. ports in Los Angeles, Houston, Miami and Savannah, Georgia. FDA officials collected several product samples and detected contamination in one sample of frozen breaded shrimp. The shipping containers and products were denied entry into the U.S. However, the FDA then learned that Walmart had received potentially affected products imported after the first detection, from shipments that did not trigger contamination alerts. Walmart immediately recalled the products, a company spokesperson said. They include Great Value brand frozen raw shrimp with lot codes 8005540-1, 8005538-1 and 8005539-1, all with best-by dates of March 15, 2027. The shrimp was sold in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. Consumers should discard the products or return them to any Walmart store for refund. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Solve the daily Crossword
Business Wire
20 minutes ago
- Business Wire
Anaergia S.r.l. Announces Agreement to Provide Infrastructure and Equipment for New Biomethane Plants in Spain
TREVIGLIO, Italy & BURLINGTON, Ontario--(BUSINESS WIRE)--Anaergia Inc. ('Anaergia', the 'Company', 'us', or 'our') (TSX:ANRG; OTCQX:ANRGF), through its subsidiary Anaergia S.r.l., has signed a Binding Agreement ('Agreement') with a leading Spanish company specializing in renewable gas infrastructure projects. Under the terms of the Agreement, Anaergia will provide a range of services as well as its cutting-edge technology and equipment for over 15 new biomethane production plants across Spain. Anaergia will be responsible for the supply and construction of concrete tanks with Triton™ digesters, a proprietary technology featuring a patented configuration that significantly enhances process efficiency. In addition, the company will supply advanced mixing systems, also part of its proprietary technology, along with other critical components to facilitate the seamless operations of the plants. Anaergia is to commence activities on the first project this month, with all the projects in the development plan expected to be fully operational and integrated into Spain's gas pipeline network within forty-eight months. Anaergia anticipates total revenue of C$184 million from this Agreement, making it the Company's largest capital sale to date. 'This agreement marks a significant milestone in advancing Spain's renewable energy sector, fostering economic growth and environmental sustainability. The scale of this historic Agreement for Anaergia highlights the advantages of our strategic focus on leveraging proprietary technologies for the benefit of our customers, and underscores our growing presence and activities in Europe,' said Assaf Onn, CEO of Anaergia. 'We are most excited about this opportunity to demonstrate the value of our innovative solutions and to support the global transition to renewable energy.' About Anaergia Anaergia is a pioneering technology company in the renewable natural gas (RNG) sector, with over 250 patents dedicated to converting organic waste into sustainable solutions such as RNG, fertilizer, and water. We are committed to addressing a significant source of greenhouse gases (GHGs) through cost-effective processes. Our proprietary technologies, combined with our engineering expertise and vast experience in facility design, construction, and operation, position Anaergia as a leader in the RNG industry. With a proven track record of delivering hundreds of innovative projects over the past decade, we are well-equipped to tackle today's critical resource recovery challenges through diverse project delivery methods. As one of the few companies worldwide offering an integrated portfolio of end-to-end solutions, we effectively combine solid waste processing, wastewater treatment, organics recovery, high-efficiency anaerobic digestion, and biomethane production. Additionally, we operate RNG facilities owned by both third parties and Anaergia. This comprehensive approach not only reduces environmental impact but also significantly lowers costs associated with waste and wastewater treatment while mitigating GHG emissions. For further information please see: Forward-Looking Statements This news release contains forward-looking information within the meaning of applicable securities legislation, which reflects Anaergia's current expectations regarding future events, including but not limited to, counterparty contractual performance, the capability of the Company's technology and performance with respect to the project objectives. Forward-looking information is based on a number of assumptions, including, but not limited to counterparty contractual performance, the full development, timing and funding of construction of the sixteen facilities, the capability of the Company's technology and performance with respect to the project objectives, the expected revenue from the agreement, and the sufficient sourcing of food waste and power generation. The Company is subject to a number of risks and uncertainties, many of which are beyond the Company's control. Such risks and uncertainties include, but are not limited to, the factors discussed under 'Risk Factors' in the Company's annual information form for the fiscal year ended December 31, 2024, and under 'Risks and Uncertainties' in the Company's most recent management's discussion and analysis. Actual results could differ materially from those projected herein. Anaergia does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required under applicable securities laws. Additional information on these and other factors that could affect Anaergia's operations or financial results are included in Anaergia's reports on file with Canadian regulatory authorities.
Business Wire
20 minutes ago
- Business Wire
AerSale ® Appoints Paul Hechenberger as Senior Vice President, General Counsel & Corporate Secretary
MIAMI--(BUSINESS WIRE)--AerSale® (NASDAQ: ASLE), a leading provider of aviation products and services, today announced the appointment of Paul Hechenberger as Senior Vice President, General Counsel & Corporate Secretary. Hechenberger brings more than four decades of legal, leadership, and aerospace experience to AerSale, with extensive expertise in complex commercial transactions, mergers and acquisitions, corporate governance, and compliance. Prior to joining AerSale, Hechenberger was a Partner with Miami-based law firm Shutts & Bowen. His previous leadership roles include serving as General Counsel at iAero Group, Deputy General Counsel at Spirit AeroSystems, General Counsel at BBA Aviation (Aftermarket Services), Chief M&A Counsel at BBA Aviation, and Corporate Counsel at Tyco Fire & Security. A U.S. Navy veteran, Hechenberger served as an EA-6B Naval Flight Officer, retiring with the rank of Captain after a combined 30 years of active and reserve service. He holds a Juris Doctor from the University of Florida, an MBA from the University of West Florida, and a BSBA from Villanova University. He is licensed to practice law in the state of Florida. "Paul's extensive legal expertise and deep understanding of the aerospace industry make him an outstanding addition to our executive team," said Nicolas Finazzo, Chief Executive Officer of AerSale. "His proven leadership and strategic counsel will be instrumental as we continue to grow our business and deliver value to our shareholders." About AerSale® AerSale serves airlines operating large jets manufactured by Boeing and Airbus and is dedicated to providing integrated aftermarket services and products designed to help aircraft owners and operators realize significant savings in the operation, maintenance and monetization of their aircraft, engines, and components. AerSale's offerings include Aircraft & Component MRO, Aircraft and Engine Sales and Leasing, Used Serviceable Material sales, and internally developed 'Engineered Solutions' to comply with regulatory mandates and/or to enhance aircraft performance and operating economics (e.g. AerSafe®, AerTrak®, and AerAware™).
